化药新药研发检测

解决方案

标准解读

推荐厂商:

上海鑫欣生物科技有限公司 上海鑫欣生物
安捷伦科技(中国)有限公司 安捷伦
沃特世科技(上海)有限公司(Waters) Waters
岛津企业管理(中国)有限公司 岛津
赛默飞色谱与质谱海德创业赛多利斯TA仪器东南科仪JYDT培安公司瑞士万通PerkinElmer百欧林上海通微淘仪科技上海纳锘实业海能技术安东帕NanoTemperbiotage日立科学仪器仪真分析仪器Molecular Devices杭州迅数上海凯来德祥贝克曼库尔特赛默飞世尔材料物性普析赛默飞世尔分子光谱美析仪器北京京科瑞达东曹TOSOHLUMEXJASCO深圳市一正科技汉邦科技香港环球分析
重置
全部品牌

检测项目:

参考标准:

化学药中主要物质含量分析检测方案

Previously it has been shown that glycerol can be regioselectively glucosylated by sucrose phosphorylase from Leuconostoc mesenteroides to form 2-O--d-glucopyranosyl glycerol.A series of compounds related to glycerol were investigated by us to determine the scope of the -glucosylation reaction of sucrose phosphorylase. Both sucrose and glucose 1-phosphate (G1P) were applied as glucosyl donor. Mono-alcohols were not accepted as substrates but several 1,2-diols were readily glucosylated, proving that the vicinal diol unit is crucial for activity. The smallest substrate that was accepted for glucosylation appeared to be ethylene glycol,which was converted to the monoglucoside for 69%. Using high acceptor and donor concentrations (up to 2.5 M), sucrose or G1P hydrolysis (with H2O being the ‘acceptor’) can be minimised. In the study cited above, a preference for glucosylation of glycerol on the 2-position has been observed. For 1,2-propanediol however, the regiochemistry appeared to be dependent on the configuration of the substrate. The (R)-enantiomer was preferentialy glucosylated on its 1-position (ratio 2.5:1), whereas the 2-glucoside is the major product for (S)-1,2-propanediol (1:4.1). d.e.ps of 71–83% were observed with a preference for the (S)-enantiomer of the glucosides of 1,2-propanediol and 1,2-butanediol and the (R)-enantiomer of the glucoside of 3-methoxy-1,2-propanediol. This is the first example of stereoselective glucosylation of a non-natural substrate by sucrose phosphorylase. 3-Amino-1,2-propanediol, 3-chloro-1,2-propanediol, 1-thioglycerol and glyceraldehyde were not accepted as substrates.
检测样品: 化药新药研发
检测项: 其他

上海鑫欣生物科技有限公司

查看联系电话
前往展位

b-受体阻滞剂中低 pH 和高 pH 条件下分离检测方案(液相色谱仪)

b-受体阻滞剂或b-肾上腺素受体阻滞剂是一类用于治疗高血压与控制心律失常的药物。b-肾上腺素受体拮抗剂可通过阻断肾上腺素及其他应激激素与神经末端的b-受体的结合而减少这些激素的影响。礼来实验室在1958 年合成出了第一种b-受体阻滞剂,但直到 1962 年才开发出首批具有临床意义的b-受体阻滞剂心得安和萘心定,并将其用于治疗心绞痛。 b-受体阻滞剂可阻断肾上腺素和去甲肾上腺素对尤其是b-肾上腺素受体的作用,而b-肾上腺素受体是调节“战斗或逃跑”反应的交感神经系统中的一部分。已知存在三种类型的b-受体,分别称为b1、b2 和b3 受体。b1-肾上腺素受体主要存在于心脏和肾脏中;b2-肾上腺素受体主要存在于肺、胃肠道、肝脏、子宫、血管平滑肌和骨骼肌中;b3-肾上腺素受体则存在于脂肪细胞中。 数量众多的b-受体阻滞剂根据其阻断b-受体的类型而分为不同种类,因此其作用也各不相同。心得安等非选择性b-受体阻滞剂能够阻断b1 和b2 受体,并对心脏、血管和呼吸道产生影响。美托洛尔等选择性b-受体阻滞剂主要阻断b1 受体,因此主要影响心脏而不影响呼吸道。而心得乐等某些b-受体阻滞剂则能够模拟肾上腺素和去甲肾上腺素的作用,并可导致血压和心率的升高。 采用填充2.7 μm 或4 μm 颗粒的Agilent Poroshell HPH C18 色谱柱在高pH 流动相下分析诸如b-受体阻滞剂等碱性化合物是一种常规方法。这些色谱柱填充表面多孔颗粒,可在方法开发中探索更宽的pH 范围。填充此类颗粒的色谱柱凭借其高效和快速的特点得到了越来越多的应用。
检测样品: 化药新药研发
检测项: 其他

安捷伦科技(中国)有限公司

查看联系电话
前往展位
< 1 2 3 ··· 9 > 前往 GO

仪器信息网行业应用栏目为您提供245篇化药新药研发检测方案,可分别用于含量测定检测、限度检查检测、注射剂及特殊剂型相关检测、组学研究检测、化合物发现检测、临床前研究检测、分子量检测,参考标准主要有等